Form D · Biotechnology

Biosceptre International Ltd

Cambridge, X0 · CIK 0001675425

Offering snapshot reported Jul 28, 2026 · SEC filing

Reported sold
$346K
Offering amount: $346K
Investors reported
10
Form D · investor count
Minimum accepted
$1.1K
Reported outside-investor minimum
First sale
Jun 25, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 28, 2026Initial$345,981No comparison10SEC filing
Jun 6, 2017Initial$237,230No comparison5SEC filing
Aug 11, 2016Initial$671,674No comparison7SEC filing
Aug 11, 2016Initial$99,270No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-592255

Source: Form D, filed Jul 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Axon Director
Jonathan Collins Director
Peter Gavin Currie Director, Executive
Andrew Walton Green Director
Michael Lovett Director
Shaun Mc Nulty Executive
Peter John Newton Director
Andrew John Scott Walton Green Director
Ronald Stafford Watts Director
Gregory Winter Director
Colin Wood Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Salisbury Hourse Station Road
Cambridge, X0, CB1 2LA
Phone: 44 1223 496 090